The pulmonary route as a way to drug repositioning in COVID-19 therapy
| Autor: | Michelle Alvares Sarcinelli, Flávia Costa Mendes de Paiva, Thalita Martins da Silva, Beatriz Ferreira de Carvalho Patricio, Helvécio Vinícius Antunes Rocha, Manuela Leal da Silva, Andressa Daniele Artico Silva, Raissa Santos de Lima |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject Drug repurposing Pharmaceutical Science Pulmonary formulations Context (language use) Review Article 02 engineering and technology Disease 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine medicine Intensive care medicine Repurposing Pharmaceutical industry media_common SARS-CoV-2 business.industry Pulmonary drug delivery 021001 nanoscience & nanotechnology Coronavirus Clinical trial Drug repositioning Drug delivery 0210 nano-technology business |
| Zdroj: | Journal of Drug Delivery Science and Technology |
| ISSN: | 1773-2247 |
| Popis: | Introduction The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society's routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. Objective Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. Method A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. Results By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. Conclusion Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field. Graphical abstract Image 1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect